Immune responses of mice with different genetic backgrounds to improved multiepitope, multitarget malaria vaccine candidate antigen FALVAC-1A.
FALVAC-1A is a second-generation multitarget, multiepitope synthetic candidate vaccine against Plasmodium falciparum, incorporating elements designed to yield a stable and immunogenic molecule. Characteristics of the immunogenicity of FALVAC-1A were evaluated in congenic (H-2(b), H-2(k), and H-2(d)) and outbred strains of mice. The influences of four adjuvants (aluminum phosphate, QS-21, Montanide ISA-720, and copolymer CRL-1005) on different aspects of the immune response were also assessed. FALVAC-1A generated strong antibody responses in all mouse strains. The highest mean enzyme-linked immunosorbent assay (ELISA) antibody concentrations against FALVAC-1A were observed in the outbred ICR mice, followed by B10.BR, B10.D2, and C57BL/6 mice, though this order varied for the different adjuvants, with no statistical differences between mouse strains. In all mouse strains, the highest anti-FALVAC-1A antibody titers in ELISAs were induced by FALVAC-1A in copolymer and ISA-720 formulations, followed by QS-21 and AlPO4. These antibodies were of all four subclasses, though immunoglobulin G1 (IgG1) predominated, with the exception of FALVAC-1A with the QS-21 adjuvant, which induced predominantly IgG2c responses. Both sporozoites and blood stages of P. falciparum were recognized by anti-FALVAC-1A sera in the immunofluorescence assay. In addition to antibody, cellular immune responses were detected; these responses were studied by examining spleen cells producing gamma interferon and interleukin-4 in enzyme-linked immunospot assays. In summary, FALVAC-1A was found to be highly immunogenic and elicited functionally relevant antibodies that can recognize sporozoites and blood-stage parasites in diverse genetic backgrounds.
Kaba
S A
SA
Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA.
Price
A
A
Zhou
Z
Z
Sundaram
V
V
Schnake
P
P
Goldman
I F
IF
Lal
A A
AA
Udhayakumar
V
V
Todd
C W
CW
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008214:Lymphocytes / Q000276:immunology; D017780:Malaria Vaccines / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D010963:Plasmodium falciparum / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000939:Epitopes; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D014614:Vaccines, Synthetic; D015847:Interleukin-4; D007371:Interferon-gamma
Vaccine. 2004 Nov 25;23(2):267-77
15531046
Vaccine. 2000 Jun 15;18(25):2902-14
10812234
Vaccine. 2002 May 22;20(17-18):2155-63
12009267
Chem Immunol. 2002;80:343-65
12058649
Int Immunopharmacol. 2008 May;8(5):717-24
18387514
Infect Immun. 2004 Oct;72(10):5775-82
15385477
Hum Vaccin. 2006 Jan-Feb;2(1):14-23
17012909
Nature. 2008 Jun 19;453(7198):1122-6
18496530
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):506-14
14744892
J Immunol. 2001 May 1;166(9):5366-73
11313372
J Immunol Methods. 2001 Jun 1;252(1-2):207-18
11334981
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1615-20
9990073
Infect Immun. 2000 Apr;68(4):2102-9
10722607
J Virol. 2003 Sep;77(17):9463-73
12915561
J Immunol. 2002 Jun 1;168(11):5499-506
12023344
Immunol Lett. 2005 Jan 31;96(2):261-75
15585332
J Immunol. 2000 Mar 15;164(6):2955-63
10706682
Vaccine. 2004 Jun 2;22(17-18):2097-102
15212010
Vaccine. 2007 Jan 15;25(5):877-85
17070628
J Exp Med. 2008 Apr 14;205(4):869-82
18362170
J Pept Res. 2002 Sep;60(3):150-8
12213124
J Immunol Methods. 2000 Aug 28;242(1-2):145-57
10986397
Annu Rev Immunol. 2005;23:69-99
15771566
Curr Protein Pept Sci. 2004 Dec;5(6):425-33
15581414
Infect Immun. 2002 Mar;70(3):1417-21
11854228
J Immunol Methods. 1998 Mar 15;212(2):187-92
9672206
Nucleic Acids Res. 2002 May 15;30(10):e43
12000848
J Immunol. 2008 Jul 1;181(1):17-21
18566365
J Infect Dis. 2006 Feb 15;193(4):563-72
16425136
Vaccine. 1994 Aug;12(11):1012-7
7526570
Vaccine. 1999 Dec 10;18(9-10):832-4
10580196
Infect Immun. 1998 Nov;66(11):5329-36
9784540
Vaccine. 2001 Sep 14;19(32):4652-60
11535313
Exp Parasitol. 2002 May;101(1):3-12
12243733
Int Immunol. 2003 Apr;15(4):505-14
12663680
Immunogenetics. 1989;29(2):92-7
2563358
Immunol Lett. 2000 May 1;72(2):119-26
10841947
J Immunol. 1997 Oct 1;159(7):3400-11
9317139
PLoS One. 2008 Jul 30;3(7):e2830
18665258
Int J Biochem Cell Biol. 2005 Apr;37(4):700-6
15694829
Infect Immun. 1996 Sep;64(9):3532-6
8751895
J Immunol. 1996 Aug 1;157(3):1176-83
8757623